Repositioning Candidate Details
| Candidate ID: | R1094 |
| Source ID: | DB06772 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Cabazitaxel |
| Synonyms: | -- |
| Molecular Formula: | C45H57NO14 |
| SMILES: | [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C |
| Structure: |
|
| DrugBank Description: | Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010. |
| CAS Number: | 183133-96-2 |
| Molecular Weight: | 835.9324 |
| DrugBank Indication: | For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. |
| DrugBank Pharmacology: | Cabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours. |
| DrugBank MoA: | Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell. |
| Targets: | Tubulin alpha-4A chain binder; Tubulin beta-1 chain binder |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|